Advertisement

Topics

"AbbVie antibody drug conjugate misses mark Phase trial∨derfield=score∨derval=desc" Drugs and Medication Database: Page 3

13:05 EDT 17th July 2019 | BioPortfolio

Here are the most relevant "AbbVie antibody drug conjugate misses mark Phase trial∨derfield=score∨derval=desc" Drugs and Medications that we have found in our database.

More Information about "AbbVie antibody drug conjugate misses mark Phase trial∨derfield=score∨derval=desc" on BioPortfolio

We have published hundreds of AbbVie antibody drug conjugate misses mark Phase trial∨derfield=score∨derval=desc news stories on BioPortfolio along with dozens of AbbVie antibody drug conjugate misses mark Phase trial∨derfield=score∨derval=desc Clinical Trials and PubMed Articles about AbbVie antibody drug conjugate misses mark Phase trial∨derfield=score∨derval=desc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AbbVie antibody drug conjugate misses mark Phase trial∨derfield=score∨derval=desc Companies in our database. You can also find out about relevant AbbVie antibody drug conjugate misses mark Phase trial∨derfield=score∨derval=desc Drugs and Medications on this site too.

Showing "AbbVie antibody drug conjugate misses mark Phase trial" Drugs and Medications 51–69 of 69

QUF

Quflora fe pediatric drops [carwin pharmaceutical associates, llc]

Quflora FE Pediatric Liquid Drops

SOV

Sovaldi [gilead sciences, inc.]

These highlights do not include all the information needed to use SOVALDI safely and effectively. See full prescribing information for SOVALDI. SOVALDI(sofosbuvir) tablets, for oral use Initial U.S. Approval: 2013

Sovaldi access [gilead sciences, inc.]

These highlights do not include all the information needed to use SOVALDI safely and effectively. See full prescribing information for SOVALDI. GILEAD ACCESS PROGRAM SOVALDI™ (sofosbuvir) tablets, for oral use Initial U.S. Approval: 2013

SUR

Survanta [abbvie inc.]

SURVANTA

SYN

Synagis [medimmune, llc]

These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS (palivizumab) injection, for intramuscular useInitial U.S. Approval: 1998

TAK

Takhzyro [dyax corp.]

These highlights do not include all the information needed to use TAKHZYRO™ safely and effectively. See full prescribing information for TAKHZYRO™. TAKHZYRO™ (lanadelumab-flyo) injection, for subcutaneous use.Initial U.S. Approval: 2018.

TAN

Tanzeum [glaxosmithkline llc]

These highlights do not include all the information needed to use TANZEUM safely and effectively. See full prescribing information for TANZEUM.TANZEUM (albiglutide) for injection, for subcutaneous useInitial U.S. Approval: 2014

TRI

Tri-vit with fluoride and iron drops [par pharmaceutical]

TRI-VIT WITH FLUORIDE 0.25 mg AND IRON DROPS Rx only

Tri-vit with fluoride drops [par pharmaceutical]

TRI-VIT WITH FLUORIDE 0.5 mg DROPS Rx only

Tri-vit with fluoride drops [par pharmaceutical]

TRI-VIT WITH FLUORIDE 0.25 mg DROPS Rx only

Tridione [abbvie inc.]

TRIDIONE® (trimethadione)Tablets

TRO

Trogarzo [theratechnologies inc.]

These highlights do not include all the information needed to use TROGARZO safely and effectively. See full prescribing information for TROGARZO. TROGARZO™ (ibalizumab-uiyk) injection, for intravenous use Initial U.S. Approval: [2018]

TYS

Tysabri [biogen inc.]

These highlights do not include all the information needed to use TYSABRI safely and effectively. See full prescribing information for TYSABRI.TYSABRI (natalizumab) injection, for intravenous useInitial U.S. Approval: 2004

ULT

Ultomiris [alexion pharmaceuticals inc.]

These highlights do not include all the information needed to use ULTOMIRIS™ safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS™ (ravulizumab-cwvz) injection, for intravenous useInitial U.S. Approval: 2018

VEN

Venclexta [abbvie inc.]

These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA. VENCLEXTA (venetoclax tablets) for oral use Initial U.S. Approval: 2016

ZEJ

Zejula [tesaro, inc.]

These highlights do not include all the information needed to use ZEJULA safely and effectively. See full prescribing information for ZEJULA. ZEJULA (niraparib) capsules, for oral useInitial U.S. Approval: 2017

ZEM

Zemplar [abbvie inc.]

These highlights do not include all the information needed to use ZEMPLAR safely and effectively. See full prescribing information for ZEMPLAR. ZEMPLAR (paricalcitol) capsules, for oral use Initial U.S. Approval: 1998

Zemplar [abbvie inc.]

These highlights do not include all the information needed to use ZEMPLAR safely and effectively. See full prescribing information for ZEMPLAR. ZEMPLAR (paricalcitol) injection, for intravenous useInitial U.S. Approval: 1998

ZIN

Zinplava [merck sharp & dohme corp.]

These highlights do not include all the information needed to use ZINPLAVA safely and effectively. See full prescribing information for ZINPLAVA. ZINPLAVA™ (bezlotoxumab) injection, for intravenous use Initial U.S. Approval: 2016



Advertisement
Quick Search
Advertisement
Advertisement